In January of 2024 we put in the requirement that you have type 2 diabetes for certain GLP-1s, and then we put in a BMI of 35 or higher for the weight loss GLP-1s
Paralysis of the stomach (gastroparesis)
11 Although not a T2D trial, SELECT (semaglutide) enrolled patients with overweight or obesity (BMI 27 kg/m 2 ) and established CVD
None of these replace a prescription, and if youre managing a condition like type 2 diabetes or obesity, you need to see a healthcare provider before making major dietary changes
Additionally, the enhanced visualization of the technology provided me with great control of the catheter
The net difference , nearly 15 percentage points , underlines a hard truth about GLP-1 therapy: its not a short-term fix